Cassava Sciences has launched the first of two Phase 3 clinical trials evaluating the safety and efficacy of simufilam, its investigational oral treatment for Alzheimer’s disease. The second trial is expected to start by year’s end, the company said in a press release. The first Phase 3 trial, called RETHINK–ALZ (NCT04994483), aims to enroll around 750 people, ages 50–87, with mild to moderate Alzheimer’s across 39 clinical sites in the U.S. and Canada. Additional overseas sites are…
You must be logged in to read/download the full post.
The post 1st Phase 3 Simufilam Trial Enrolling Patients; 2nd Expected by Year’s End appeared first on BioNewsFeeds.